• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CC-1065与特定寡脱氧核苷酸双链体之间加合物的表征

Characterization of an adduct between CC-1065 and a defined oligodeoxynucleotide duplex.

作者信息

Needham-VanDevanter D R, Hurley L H, Reynolds V L, Theriault N Y, Krueger W C, Wierenga W

出版信息

Nucleic Acids Res. 1984 Aug 10;12(15):6159-68. doi: 10.1093/nar/12.15.6159.

DOI:10.1093/nar/12.15.6159
PMID:6473105
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC320064/
Abstract

CC-1065 is a potent antitumor antibiotic produced by Streptomyces zelensis. The drug binds covalently through N-3 of adenine and lies within the minor groove of DNA. Previous studies indicated that CC-1065 reacted with adenine in DNA to yield a thermally labile product that could be used to reveal its sequence specificity. These studies also provided insight into a DNA sequence (5'-CGGAGTTAGGGGCG-3') which should bind one molecule of CC-1065 in an unambiguous manner. This sequence, which contains the CC-1065 adenine binding site within the sequence 5'-TTA-3' was chemically synthesized together with the complementary strand. CC-1065 reacted with the oligoduplex to give an adduct that maintained the B-DNA form and had a final CD spectrum similar to those of the CC-1065 complexes formed with calf thymus DNA. The above 14mer was 5' end-labelled with 32P, annealed with its complementary strand, reacted with CC-1065 and heated. Drug-mediated strand breakage was evaluated on a sequencing gel. A single break occurred in the labelled strands to give a fragment that migrated as an 8.5mer; subsequent piperidine treatment produced a fragment that migrated as a 7mer, which is the size expected from the known binding of CC-1065 at adenine in 5'-TTA-3' sequences.

摘要

CC - 1065是由泽链霉菌产生的一种强效抗肿瘤抗生素。该药物通过腺嘌呤的N - 3共价结合,并位于DNA的小沟内。先前的研究表明,CC - 1065与DNA中的腺嘌呤反应生成一种热不稳定产物,可用于揭示其序列特异性。这些研究还深入了解了一个DNA序列(5'-CGGAGTTAGGGGCG-3'),该序列应以明确的方式结合一分子的CC - 1065。这个序列在5'-TTA-3'序列中包含CC - 1065腺嘌呤结合位点,它与互补链一起被化学合成。CC - 1065与寡双链体反应生成一种加合物,该加合物保持B - DNA形式,其最终的圆二色光谱与用小牛胸腺DNA形成的CC - 1065复合物相似。上述14聚体用32P进行5'端标记,与互补链退火,与CC - 1065反应并加热。在测序凝胶上评估药物介导的链断裂。标记链中出现了一个单一的断裂,产生了一个迁移为8.5聚体的片段;随后用哌啶处理产生了一个迁移为7聚体的片段,这是根据CC - 1065在5'-TTA-3'序列中腺嘌呤处的已知结合预期的大小。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fa7/320064/0d6399ef59f7/nar00333-0214-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fa7/320064/0d6399ef59f7/nar00333-0214-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fa7/320064/0d6399ef59f7/nar00333-0214-a.jpg

相似文献

1
Characterization of an adduct between CC-1065 and a defined oligodeoxynucleotide duplex.CC-1065与特定寡脱氧核苷酸双链体之间加合物的表征
Nucleic Acids Res. 1984 Aug 10;12(15):6159-68. doi: 10.1093/nar/12.15.6159.
2
Determination of the major tautomeric form of the covalently modified adenine in the (+)-CC-1065-DNA adduct by 1H and 15N NMR studies.通过¹H和¹⁵N核磁共振研究确定(+)-CC-1065-DNA加合物中经共价修饰的腺嘌呤的主要互变异构形式。
Biochemistry. 1990 Oct 16;29(41):9503-7. doi: 10.1021/bi00493a002.
3
Demonstration of the asymmetric effect of CC-1065 on local DNA structure using a site-directed adduct in a 117-base-pair fragment from M13mp1.使用来自M13mp1的117个碱基对片段中的位点定向加合物证明CC - 1065对局部DNA结构的不对称效应。
Proc Natl Acad Sci U S A. 1987 Sep;84(18):6412-6. doi: 10.1073/pnas.84.18.6412.
4
Construction and characterization of a site-directed CC-1065-N3-adenine adduct within a 117 base pair DNA restriction fragment.在一个117个碱基对的DNA限制性片段内构建和表征位点特异性CC - 1065 - N3 -腺嘌呤加合物。
Biochemistry. 1986 Dec 30;25(26):8430-6. doi: 10.1021/bi00374a016.
5
Recognition and repair of the CC-1065-(N3-adenine)-DNA adduct by the UVRABC nucleases.UVRABC核酸酶对CC - 1065 -(N3 -腺嘌呤)- DNA加合物的识别与修复
Biochemistry. 1988 Feb 9;27(3):893-901. doi: 10.1021/bi00403a009.
6
Reaction of the antitumor antibiotic CC-1065 with DNA. Location of the site of thermally induced strand breakage and analysis of DNA sequence specificity.抗肿瘤抗生素CC-1065与DNA的反应。热诱导链断裂位点的定位及DNA序列特异性分析。
Biochemistry. 1985 Oct 22;24(22):6228-37. doi: 10.1021/bi00343a029.
7
An NMR study of the covalent and noncovalent interactions of CC-1065 and DNA.CC-1065与DNA的共价和非共价相互作用的核磁共振研究。
Biochemistry. 1990 Mar 20;29(11):2852-60. doi: 10.1021/bi00463a031.
8
Determination of the structural features of (+)-CC-1065 that are responsible for bending and winding of DNA.确定负责使DNA弯曲和缠绕的(+)-CC-1065的结构特征。
Chem Res Toxicol. 1991 Mar-Apr;4(2):203-13. doi: 10.1021/tx00020a013.
9
Mechanism of interaction of CC-1065 (NSC 298223) with DNA.CC-1065(NSC 298223)与DNA的相互作用机制。
Cancer Res. 1982 Jul;42(7):2821-8.
10
Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity.
Science. 1984 Nov 16;226(4676):843-4. doi: 10.1126/science.6494915.

引用本文的文献

1
Finding potential DNA-binding compounds by using molecular shape.
J Comput Aided Mol Des. 1994 Dec;8(6):731-50. doi: 10.1007/BF00124018.
2
Theoretical study of the sequence specificity in the covalent binding of the antitumor drug CC-1065 to DNA.抗肿瘤药物CC-1065与DNA共价结合中序列特异性的理论研究。
Nucleic Acids Res. 1987 Jul 24;15(14):5775-85. doi: 10.1093/nar/15.14.5775.

本文引用的文献

1
CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis, and cell survival.
Cancer Res. 1982 Sep;42(9):3532-7.
2
Mechanism of interaction of CC-1065 (NSC 298223) with DNA.CC-1065(NSC 298223)与DNA的相互作用机制。
Cancer Res. 1982 Jul;42(7):2821-8.
3
An efficient method for the sequence analysis of oligodeoxyribonucleotides.一种用于寡脱氧核糖核苷酸序列分析的高效方法。
Anal Biochem. 1983 Feb 1;128(2):281-6. doi: 10.1016/0003-2697(83)90376-7.
4
CC-1065 (NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA.CC-1065(NSC 298223),一种能与双链DNA强烈相互作用的新型抗肿瘤药物。
Cancer Res. 1982 Mar;42(3):999-1004.
5
Mechanism of bleomycin action: in vitro studies.博来霉素作用机制:体外研究
Life Sci. 1981 Feb 16;28(7):715-27. doi: 10.1016/0024-3205(81)90153-3.